Algernon Pharmaceuticals Dmt Stroke Program

May 31, 2026
Media Summary: Interview with CEO Christopher Moreau and host Cyndi Edwards regarding news about the next steps in CEO Chris Moreau discusses the recent Ifendprodil transaction with Seyltx and plans and milestones for

Algernon Pharmaceuticals Dmt Stroke Program - Detailed Analysis & Overview

Interview with CEO Christopher Moreau and host Cyndi Edwards regarding news about the next steps in CEO Chris Moreau discusses the recent Ifendprodil transaction with Seyltx and plans and milestones for

Photo Gallery

Algernon Pharmaceuticals DMT Stroke Clinical Program
Algernon Pharmaceuticals DMT Stroke Program Update and Recap with CEO Christopher Moreau
Algernon launching research program for treatment of stroke using Psychedelic drug DMT
Algernon Pharmaceutical’s DMT Clinical Research Program for Stroke receives positive FDA feedback
Market One - Algernon Pharmaceuticals - First Company to Investigate DMT as a Treatment for Stroke
Algernon Pharmaceuticals Forms Algernon NeuroScience Subsidiary to Advance DMT Stroke Program
Algernon Pharmaceuticals plans Phase 2 stroke and TBI study after successful DMT single dose study
Algernon is trailblazing a new treatment option for stroke – could it work?
Algernon Pharmaceutical files for Clinical Trial and Ethics approval for Phase 1 DMT Stroke study
Algernon Pharmaceuticals Phase 1 DMT stroke study will start in September of 2022
Algernon Pharmaceuticals gains approval for Phase 1 clinical study of DMT for treatment of stroke
Algernon Pharmaceutical’s preclinical study of DMT for stroke confirms growth of Neurons by 40%

Related Updates

Algernon Pharmaceuticals DMT Stroke Clinical Program Algernon Pharmaceuticals DMT Stroke Program Update and Recap with CEO Christopher Moreau Algernon launching research program for treatment of stroke using Psychedelic drug DMT Algernon Pharmaceutical’s DMT Clinical Research Program for Stroke receives positive FDA feedback Market One - Algernon Pharmaceuticals - First Company to Investigate DMT as a Treatment for Stroke Algernon Pharmaceuticals Forms Algernon NeuroScience Subsidiary to Advance DMT Stroke Program Algernon Pharmaceuticals plans Phase 2 stroke and TBI study after successful DMT single dose study Algernon is trailblazing a new treatment option for stroke – could it work? The Future Of Affordable Housing: Discover Modern Prefab Homes Under $100k Discover Hidden Gems In NJ Craigslist: Top Deals Found Today Save Up To 50 Percent At La Fitness Gyms Without Sneaky Fees Can You Crack The Code Of The Anoai Family Tree And Unlock Hidden Family Secrets? Was Jim Lombardo A True Original Or Tragic Figure In Shameless? Pittsburgh PA Classifieds: Your Daily Fix For Everything Local The 5 Sneaky Reasons Why You Get Chronic Sniffles Every Time You Hook Up J Reuben Long Detention Center Bookings: A Rise In Local Incarcerations?
Sponsored
Sponsored
View Detailed Profile
Algernon Pharmaceuticals DMT Stroke Clinical Program

Algernon Pharmaceuticals DMT Stroke Clinical Program

Join Christopher J. Moreau, CEO of

Algernon Pharmaceuticals DMT Stroke Program Update and Recap with CEO Christopher Moreau

Algernon Pharmaceuticals DMT Stroke Program Update and Recap with CEO Christopher Moreau

Interview with CEO Christopher Moreau and host Cyndi Edwards regarding news about the next steps in

Sponsored
Algernon launching research program for treatment of stroke using Psychedelic drug DMT

Algernon launching research program for treatment of stroke using Psychedelic drug DMT

Algernon Pharmaceuticals

Algernon Pharmaceutical’s DMT Clinical Research Program for Stroke receives positive FDA feedback

Algernon Pharmaceutical’s DMT Clinical Research Program for Stroke receives positive FDA feedback

Algernon Pharmaceuticals

Market One - Algernon Pharmaceuticals - First Company to Investigate DMT as a Treatment for Stroke

Market One - Algernon Pharmaceuticals - First Company to Investigate DMT as a Treatment for Stroke

Market One -

Sponsored
Algernon Pharmaceuticals Forms Algernon NeuroScience Subsidiary to Advance DMT Stroke Program

Algernon Pharmaceuticals Forms Algernon NeuroScience Subsidiary to Advance DMT Stroke Program

Algernon Pharmaceuticals

Algernon Pharmaceuticals plans Phase 2 stroke and TBI study after successful DMT single dose study

Algernon Pharmaceuticals plans Phase 2 stroke and TBI study after successful DMT single dose study

Algernon Pharmaceuticals

Algernon is trailblazing a new treatment option for stroke – could it work?

Algernon is trailblazing a new treatment option for stroke – could it work?

Christopher J. Moreau, CEO of

Algernon Pharmaceutical files for Clinical Trial and Ethics approval for Phase 1 DMT Stroke study

Algernon Pharmaceutical files for Clinical Trial and Ethics approval for Phase 1 DMT Stroke study

Algernon Pharmaceuticals

Algernon Pharmaceuticals Phase 1 DMT stroke study will start in September of 2022

Algernon Pharmaceuticals Phase 1 DMT stroke study will start in September of 2022

Algernon Pharmaceuticals

Algernon Pharmaceuticals gains approval for Phase 1 clinical study of DMT for treatment of stroke

Algernon Pharmaceuticals gains approval for Phase 1 clinical study of DMT for treatment of stroke

Algernon Pharmaceuticals

Algernon Pharmaceutical’s preclinical study of DMT for stroke confirms growth of Neurons by 40%

Algernon Pharmaceutical’s preclinical study of DMT for stroke confirms growth of Neurons by 40%

Algernon Pharmaceuticals

Algernon gets approval for groundbreaking phase 1 study of DMT for stroke

Algernon gets approval for groundbreaking phase 1 study of DMT for stroke

Christopher Moreau, CEO & Director of

Algernon NeuroScience testing psychedelic DMT to treat Stroke

Algernon NeuroScience testing psychedelic DMT to treat Stroke

Algernon Pharmaceuticals

Algernon Pharmaceuticals (AGN) CEO Chris Moreau Outlines DMT Stroke Research and Ifendprodil Plans

Algernon Pharmaceuticals (AGN) CEO Chris Moreau Outlines DMT Stroke Research and Ifendprodil Plans

CEO Chris Moreau discusses the recent Ifendprodil transaction with Seyltx and plans and milestones for

Algernon Pharmaceuticals looks to highly regarded UK company to conduct Phase 1 DMT stroke study

Algernon Pharmaceuticals looks to highly regarded UK company to conduct Phase 1 DMT stroke study

Algernon Pharmaceuticals

Algernon Pharmaceuticals completes manufacturing of Psychedelic Drug DMT for Phase 1 and 2 study

Algernon Pharmaceuticals completes manufacturing of Psychedelic Drug DMT for Phase 1 and 2 study

Algernon Pharmaceuticals

DMT = +40% Neurons | Christopher Moreau, CEO Algernon—New Hope 4 Healing the Brain | DMT Conference

DMT = +40% Neurons | Christopher Moreau, CEO Algernon—New Hope 4 Healing the Brain | DMT Conference

Is there proof

Algernon Pharmaceuticals established Optimum Treatment Period for DMT

Algernon Pharmaceuticals established Optimum Treatment Period for DMT

Algernon Pharmaceuticals

Algernon NeuroScience begins human trials using DMT to treat stroke

Algernon NeuroScience begins human trials using DMT to treat stroke

Algernon Pharmaceuticals

Related Video Content

Flowers for Algernon - Wikipedia information

Flowers for Algernon is a short novelette [5] by American author Daniel Keyes, which he later expanded into a novel...

Flowers for Algernon by Daniel Keyes | Full Text information

Read about Flowers for Algernon by Daniel Keyes — analysis, themes, and discussion. A man's experimental journey from...

Algernon | Flowering Plant, Plant Genus, Plant Species | Britannica information

Algernon, fictional character, a witty man-about-town in Oscar Wilde ’s play The Importance Of Being Earnest (1895)....

Flowers for Algernon by Daniel Keyes | Goodreads information

Flowers for Algernon is a beautiful and poignant story. Daniel Keyes effectively teaches us about the issue of living...

Flowers for Algernon: Full Book Summary | SparkNotes information

A short summary of Daniel Keyes's Flowers for Algernon. This free synopsis covers all the crucial plot points of...